India is increasingly becoming a preferred destination for the global pharmaceutical supply chain, according to a recent report by Macquarie. The country’s strong manufacturing capabilities, cost efficiency, and regulatory reforms are driving its growth in the sector. The report highlights that India’s pharmaceutical industry, already valued at over $50 billion, is poised for further expansion as global companies seek to reduce dependence on China. With a well-established ecosystem of raw material suppliers, skilled workforce, and world-class production facilities, India offers a competitive edge in active pharmaceutical ingredients (APIs) and generic medicines. Government initiatives such as the Production-Linked Incentive (PLI) scheme and policy support for domestic API production have further strengthened India’s position. Additionally, rising investments in research and development (R&D) and the adoption of advanced technologies, including AI-driven drug discovery and digital healthcare solutions, are making India an attractive hub for global pharma giants. With increasing partnerships, export growth, and a favorable policy landscape, India is set to play a crucial role in ensuring a resilient and diversified global pharmaceutical supply chain. As multinational firms continue to shift their sourcing strategies, India stands out as a key beneficiary of this transformation. #PharmaceuticalIndustry #IndiaPharma #GlobalSupplyChain #APIs #DrugManufacturing #HealthcareInnovation #MedTech #PharmaGrowth #MakeInIndia #PLI #HealthcareStartups #DigitalHealth #Biopharma #R&D #AIinHealthcare #PharmaExports #SupplyChainResilience #HealthcareTech #Dseidehealthcarenetwork Source: Financial Express

Higher tariffs imposed by the U.S. on certain pharmaceutical imports from India are unlikely to impact the country’s competitive edge in the American market, according to industry experts. India remains a dominant player in the U.S. pharmaceutical sector, supplying around 40% of generic drugs. Factors such as cost-efficient manufacturing, a skilled workforce, and regulatory compliance continue to support India’s strong market presence. While the Biden administration has increased tariffs on some Chinese pharmaceutical ingredients, India is seen as a reliable alternative for drug production. The Indian pharmaceutical industry has also been expanding its manufacturing capabilities, reducing dependence on Chinese raw materials. This shift enhances supply chain resilience and ensures steady exports to the U.S. Industry leaders believe that India’s ability to produce affordable, high-quality medicines will help it withstand tariff changes. Additionally, ongoing investments in research and development (R&D), innovation, and adherence to U.S. FDA standards reinforce India’s position as a preferred supplier. Despite potential short-term cost pressures, Indian pharmaceutical firms are expected to remain competitive by leveraging economies of scale and focusing on high-value drug formulations. The long-term outlook remains positive, driven by global demand for affordable medicines and strong bilateral trade relations. #IndiaPharma #USPharmaMarket #GenericDrugs #PharmaExports #TradeRelations #HealthcareIndustry #MedTech #Tariffs #PharmaManufacturing #SupplyChain #AffordableMedicine #PharmaInnovation #DrugSupply #FDACertified #HealthTech #GlobalPharma #PharmaceuticalIndustry #dseidehealthcarenetwork Source: Financial Express

𝐖𝐨𝐫𝐤𝐬𝐡𝐨𝐩 𝐑𝐞𝐠𝐢𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧 𝗖𝗮𝗹𝗹 : 𝐖𝐨𝐫𝐤𝐬𝐡𝐨𝐩 𝐟𝐨𝐫 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐏𝐫𝐨𝐜𝐮𝐫𝐞𝐦𝐞𝐧𝐭 𝐓𝐞𝐚𝐦𝐬 𝐨𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐏𝐫𝐨𝐜𝐮𝐫𝐞𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐒𝐮𝐩𝐩𝐥𝐲 𝐂𝐡𝐚𝐢𝐧 𝐏𝐫𝐚𝐜𝐭𝐢𝐜𝐞𝐬 3rd Edition of HOSPEX 2024 , Kerala's only medical & healthcare expo in Kerala happening from Sep 27-29th at Kochi. Workshop for 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗣𝗿𝗼𝗰𝘂𝗿𝗲𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝗦𝘂𝗽𝗽𝗹𝘆 𝗖𝗵𝗮𝗶𝗻 𝗣𝗿𝗮𝗰𝘁𝗶𝗰𝗲𝘀 𝗶𝘀 𝘀𝗰𝗵𝗲𝗱𝘂𝗹𝗲𝗱 𝗼𝗻 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝟮𝟴𝗺 𝟮𝟬𝟮𝟰 𝗯𝗲𝘁𝘄𝗲𝗲𝗻 𝟮.𝟬𝟬 𝗽𝗺 𝘁𝗼 𝟱.𝟯𝟬 𝗽𝗺 𝗣𝗿𝗼𝗴𝗿𝗮𝗺 𝗜𝗻𝗳𝗼 : Date 📅28th September 2024 Time 2.00 pm to 5.30 pm Venue 📌KINFRA International Exhibition Centre, Kakkanad, Kochi Fee 💰Rs. 500 ( including GST) 𝗢𝗯𝗷𝗲𝗰𝘁𝗶𝘃𝗲 Since Healthcare Services and Products are under Regulations globally, its imperative for Healthcare Service organisations to ensure that their supply chain partners, value chain partners and In house teams who are responsible for Regulations adhere to the Regulatory compliance prevailing in the country. 𝗧𝗼𝗽𝗶𝗰𝘀 𝗰𝗼𝘃𝗲𝗿𝗲𝗱: a. Building Authentic Healthcare Supply Chain – Regulations b. Hospital Procurement and Supply chain Practices c. Refurbished Medical Equipments and Devices and their potential risks d. Regulatory Compliance e. Overview of the Medical Device Standards f. Biomedical / Procurement practices in healthcare - skill development 𝐖𝐡𝐨 𝐬𝐡𝐨𝐮𝐥𝐝 𝐀𝐭𝐭𝐞𝐧𝐝: Healthcare Professionals who are in-charge of Procurement Practices in Hospitals and other Healthcare Settings a. Clinical Teams b. Biomedical Engineers c. Finance , Operations Teams d. Procurement / Purchase Teams e. Supply Chain Teams Use the QR code given in the poster to scan and register for the workshop OR Use the 𝙡𝙞𝙣𝙠 given below to register and make payment https://lnkd.in/gwc5C2Dz 𝗙𝗼𝗿 𝗶𝗻𝗳𝗼, 𝗰𝗹𝗮𝗿𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀, 𝗿𝗲𝗮𝗰𝗵 : Ms.Padma Sriramakrishnan 📩Email: info@events.healthcare; WA: 91 7338992778 Do watch out this space for daily announcements Please visit https://hospex.in/ to know more about the expo and other conferences at Hospex. Association of Indian Medical Device Industry (AIMED) Association of Diagnostics Manufacturers of India (ADMI) Kerala Medical Technology Consortium (KMTC) Healthcare Events Kerala Startup Mission Smart Hospitals QAI - Quality and Accreditation Institute Kerala State Industrial Development Corporation (KSIDC) BSI AHMP India Foundation Indian Medical Association (HQs) Indian Association Of Medical Devices Distributors Arun krishna Bhupendra Kumar Rana Soumya TS Rama Venugopal Rehma Javeed. #HOSPEXHealthcareExpo2024 #Workshops #Conferences #MedicalExpo #KnowledgeSessions #GoodProcurementPractices #BiomedicalEngineers #ProcurementTeams #KeralaHealthcare #KeralaMedTechEcosystem #KeralaStartups #KeralaHospitals #medicaldevices #supplychainmanagement